ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study
Launched by UMEÅ UNIVERSITY · Nov 22, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ULRICA study is looking at how quickly fluid is removed from patients undergoing chronic hemodialysis (HD) and whether this affects heart health. During HD, patients often retain extra water, which is removed through a process called ultrafiltration. The researchers want to find out if the speed at which this fluid is removed can change the levels of certain heart markers in patients. This information could help doctors improve how they manage fluid removal during HD, potentially leading to better heart health outcomes for patients.
To participate in the study, you must be an adult HD patient who has gained a certain amount of weight (at least 2.5% of your target weight) over the three days before joining. You should also be able to understand the study details and give your consent. However, if you have a serious infection or uncontrolled high phosphate levels, you won't be able to take part. If you join, you can expect to help researchers learn more about the relationship between fluid removal speed and heart health, which could help improve treatment for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult HD patients with an intra-dialytic weight gain (IDWG) ≥2.5% of target weight over the long interval (3 days) prior to inclusion.
- • Patients need to be able to understand the study information
- • Patients need to be able to give consent.
- Exclusion Criteria:
- • Active systemic inflammatory state such as extensive malignancy or acute septic infection.
- • Uncontrolled hyperphosphatemia decided by the local routine of the physician (due to somewhat decreased efficacy of the low flux filter to eliminate phosphate)
About Umeå University
Umeå University, a leading research institution in Sweden, is dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge technology and expert knowledge across various fields to address critical health challenges. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices are designed to generate robust scientific evidence, ultimately contributing to improved health outcomes and informed medical practices. Umeå University strives to foster a dynamic research environment that supports the development of new therapies and enhances the understanding of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Umea, , Sweden
Patients applied
Trial Officials
Bernd Stegmayr, MD, PhD
Principal Investigator
Umea University, Umea, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported